ReviewCells2026
Controlled Generation of Dehydroascorbic Acid: A New Mechanistic Framework for High-Dose Vitamin C Anticancer Therapy.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reviews pharmacological strategies targeting key metabolic pathways in cancer cells and highlights their inherent limitations, including metabolic plasticity and lack of selectivity. It is proposed that these vulnerabilities can be addressed through a global redox-based approach using high-dose vitamin C. Evidence suggests that the anticancer activity of vitamin C is mediated by its oxidation to dehydroascorbic acid (DHA). Although DHA cannot be administered directly due to its instability, it can be generated in situ within the circulatory system. Once taken up by cancer cells, DHA perturbs multiple redox-sensitive processes, leading to depletion of NADPH and collapse of cellular redox homeostasis. We present a mechanistic framework outlining how controlled generation of DHA may enable a more robust and clinically effective anticancer strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.